The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for ...
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...
What’s inside this Plumpy’Nut® sachet that has saved millions of children? Plumpy’Nut®, also known as ready-to-use therapeutic food (RUTF), is a high-energy peanut paste containing sugar, vegetable ...
BioArctic AB (publ) announced that the US Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) ...
Jan 15, 2025 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for ...
The company’s commitment to Alzheimer’s treatments, particularly with Leqembi, has faced slower-than-expected revenue growth. This has pressured Biogen as it attempts to compensate for ...
WASHINGTON — Have you always dreamed of driving a giant peanut? Well, Planters might have just the nutty job for you. Hormel Foods, the makers of Planters, is hiring three full-time crew members ...
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback